最新消息
News
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation漢康生技於2026 ASCO GI消化道腫瘤大會發表 HCB101 聯合標準治療在二線胃癌之臨床數據
HanchorBio Reports High Objective Response Rate with HC […]
1 月 09, 2026
Read more
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more
【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]
12 月 03, 2025
Read more
漢康生技三靶點融合蛋白HCB301完成兩個劑量組安全性評估 全球臨床推進再跨一步
漢康生技（HanchorBio, KY-7827）宣布，其以自主 FBDB™ 多功能融合蛋白平台 開發的 三靶點創新藥 HCB301，已完成臨床一期前兩個劑量組安全性觀察，結果顯示耐受性良好，具臨床開發潛力。HCB301 兼具阻斷 SIRPα-CD47、PD-1/PD-L1 及 TGFβ 三大機制，能同時啟動先天與適應性免疫、克服腫瘤免疫抑制，為難治型癌症帶來新療法。該試驗（NCT06487624）正於中美兩地進行，台灣審查中，顯示漢康在免疫融合蛋白領域的全球開發邁出重要一步。
11 月 11, 2025
Read more
HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ 漢康生技在SITC 2025公佈HCB301臨床前資料首創三特異性免疫療法靶向SIRPα-CD47、PD-1/PD-L1和TGFβ
Novel fusion protein shows potent macrophage activation […]
11 月 06, 2025
Read more
漢康HCB101再現臨床突破 頭頸癌試驗起始低劑量組患者2/2出現腫瘤大幅縮小
全球臨床階段生技公司漢康生技（7827）宣布，旗下免疫治療新藥HCB101在臨床試驗中再度傳來捷報。繼二線胃癌 […]
10 月 30, 2025
Read more
漢康HCB101二線胃癌最新數據亮眼 近九成患者腫瘤顯著縮小
全球臨床階段生技公司漢康生技（7827）公布旗下免疫治療新藥 HCB101 的最新臨床試驗數據，顯示該藥在晚期 […]
10 月 29, 2025
Read more